E822-1968
E822-1968 is an UT-A2 inhibitor with a human IC50 of 0.44 μM. E822-1968 blocks urea transport mediated by UT-A2. E822-1968 can be used for the study of hyponatremia and edema associated with congestive heart failure, nephrotic syndrome, and cirrhosis.
For research use only. We do not sell to patients.
- CAS No.: 1037259-63-4
- Formula: C19H19N3O3
- Molecular Weight:337.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
E822-1968 potently inhibits UT-A2-mediated urea transport in UT-A2-overexpressing HEK293F cells with an IC50 of 0.44 μM[1].
E822-1968 weakly inhibits UT-A3-mediated urea transport in UT-A3-overexpressing HEK293F cells with an IC50 of 3.42 μM[1].
E822-1968 (10 nM-100 μM; 50 seconds) does not inhibit UT-B-mediated urea transport in UT-B-overexpressing HEK293F cells[1].
E822-1968 (1-10 μM; 30 minutes) does not inhibit rat UT-A1-mediated urea transport in stably expressing MDCK cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1037259-63-4
-
Molecular Weight 337.37
-
Formula C19H19N3O3
-
SMILES
COC1=CC(CNC(C2=CC(C3=CC=CC(OC)=C3)=NN2)=O)=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)